Cullinan Therapeutics’ (CGEM) “Buy” Rating Reaffirmed at HC Wainwright

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $33.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 318.25% from the stock’s current price. Separately, Morgan Stanley reiterated an […]